Senate Minority Leader McConnell Tweets Statement On Debt-Limit Crisis (Link To Full Statement)

https://twitter.com/LeaderMcConnell/status/1445814140979740679

October 6, 2021

1 minute read

My new statement on the Democrats’ self-created debt limit crisis: pic.twitter.com/XwuqyS9oZ0

— Leader McConnell (@LeaderMcConnell) October 6, 2021

Jazz Pharmaceuticals Q4 EPS $4.21 Beats $3.63 Estimate, Sales $896.73M Beat $865.88M Estimate

By Benzinga Newsdesk

Today, 10:42 PM

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $4.21 per share which beat the analyst consensus estimate of $3.63 by 15.98 percent. This is a 5.25 percent increase over earnings of $4.00 per share from

JAZZ

General
News

Aramco Invests In Renault & Geely’s Powertrain Tech Company – What’s On The Cards?

By Shivani Kumaresan

Today, 10:42 PM

Petroleum company Saudi Aramco has signed a letter of intent with Renault ADR (OTC:RNLSY) and Geely Automobile Holdings Ltd.(OTC:GELYY) to become a potential minority stakeholder…

GELYY

Mersana Stock Gains On FDA Orphan Drug Designation For Gastric Cancer Drug

By Ragothaman Srinivasan

Today, 10:42 PM

Mersana Therapeutics, Inc. (NASDAQ: MRSN) received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its drug candidate XMT-2056 or the treatment of gastric cancer. The company is planning to start a clinical study evaluating XMT-2056 for gastric and other cancers.

MRSN

Credit Suisse Maintains Neutral on Freshpet, Lowers Price Target to $170

By Benzinga Newsdesk

Today, 10:42 PM

Credit Suisse analyst Robert Moskow maintains Freshpet (NASDAQ:FRPT) with a Neutral and lowers the price target from $180 to $170.

FRPT

Senate Minority Leader McConnell Tweets Statement On Debt-Limit Crisis (Link To Full Statement)

Related Posts

Jazz Pharmaceuticals Q4 EPS $4.21 Beats $3.63 Estimate, Sales $896.73M Beat $865.88M Estimate

Aramco Invests In Renault & Geely’s Powertrain Tech Company – What’s On The Cards?

Mersana Stock Gains On FDA Orphan Drug Designation For Gastric Cancer Drug

Credit Suisse Maintains Neutral on Freshpet, Lowers Price Target to $170